(Q57903637)

2

0 references

Ozden Altundag

1 reference

ORCID Public Data File 2021

author name string

N. Colombo

1

0 references

F. Amant

3

0 references

A. González-Martín

5

0 references

J. Ledermann

6

0 references

C. Marth

7

0 references

R. Nout

8

0 references

D. Querleu

9

0 references

M.R. Mirza

10

0 references

C. Sessa

Prognostic factors for uterine cancer in reproductive-aged women

11

0 references

publication date

2 December 2015

0 references

published in

Annals of Oncology

0 references

volume

27

0 references

issue

1

0 references

page(s)

16-41

0 references

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial carcinoma in women aged 40 years and younger

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Metabolic syndrome and endometrial cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Metabolic syndrome and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Association between diabetes, diabetes treatment and risk of developing endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Reproductive factors and the risk of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial cancer in women 40 years old or younger

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Radiologic staging in patients with endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Fertility-sparing in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Fertility-sparing therapy in young women with endometrial cancer: 2010 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Diagnostic implications of p16 expression in serous papillary endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Clinically occult tubal and ovarian high-grade serous carcinomas presenting in uterine samples: diagnostic pitfalls and clues to improve recognition of tumor origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Transvaginal ultrasound assessment of myometrial and cervical stromal invasion in women with endometrial cancer: interobserver reproducibility among ultrasound experts and gynecologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Imaging in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Intra-operative frozen section results reliably predict final pathology in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

HE4 is an independent prognostic marker in endometrial cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Lymph node sampling and survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Classification of radical hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Clinical outcomes of uterine carcinosarcoma: results of 94 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Survival after relapse in patients with endometrial cancer: results from a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Multicenter cohort study on treatment results and risk factors in stage II endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Combined chemotherapy and radiation improves survival for node-positive endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The importance of chemotherapy and radiation in uterine papillary serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Image-based three-dimensional conformal brachytherapy for medically inoperable endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Molecular pathology of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Endometrial carcinoma: molecular alterations involved in tumor development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Markers for individualised therapy in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Emerging therapeutic targets in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Current status of molecular biomarkers in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Molecular targets and targeted therapeutics in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Design issues in randomized phase II/III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV484